Full Press Release Details
Labs Appoints WEX CFO and Former Revlon
CFO, Roberto Simon, to Board of Directors
York, NY, November 10, 2020 -
Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has appointed Roberto Simon
to its board of directors and as the chair of its audit committee. Following his appointment, the board now has eight members,
with six serving as independent directors.
seasoned, global executive, Mr. Simon has held several senior leadership roles over
the last 19 years where he has managed the organic and acquisitive growth for large, international
firms operating across the Americas, Europe and Africa.
Simon currently serves as CFO of WEX (NYSE: WEX), a $6+ billion fintech services provider. He previously served as CFO
of Revlon (NYSE: REV), overseeing the global finance and IT operations of the top beauty brand as it grew to nearly
$2 billion in annual sales.
to Revlon, Mr. Simon served in several senior roles and lastly as CFO of The Colomer Group, a private equity-owned beauty care
company with $600 million in annual revenue. He was responsible for Colomer's SAP, finance operations, integrations, acquisitions
and divestments. He led the sale of Colomer to Revlon, and the integration of its financial and IT operations post-merger.
greatly strengthens our board with his extensive, senior-level executive experience in leading multinational companies involved
in consumer goods and fintech," stated Justin Schreiber, chairman and CEO of Conversion Labs. "As our new audit committee
chair, Roberto will provide board-level guidance of our financial operations and infrastructure with a focus on scale and continued
acceleration of our growth opportunities. The independence of our corporate governance is also now better positioned to satisfy
Nasdaq's listing requirements."
look forward to benefiting from Roberto's expertise and guidance as we focus on scaling our telemedicine business,"
added Schreiber. "Given his extensive experience in M&A transactions and integrations, we expect Roberto to play a key
role in this important aspect of our growth strategy."
Mr. Simon: "As someone long involved in the global consumer markets, I'm impressed with the platform Conversion Labs
has built to address the vast opportunities emerging in the direct-to-consumer telehealth space. The company's accomplishments
this year have been nothing short of phenomenal, and I'm looking forward to contributing my expertise and experience at
this pivotal time in its growth and development."
Simon speaks five languages, including English, Spanish, Italian, French and Catalan. He holds bachelor's degrees in business
administration, and a master's degree in business administration from ESADE Business School in Barcelona.
Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine
virtual medical treatment with prescription medications and unique over-the-counter products. Its network
of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn
more, visit Conversionlabs.com.
Cautions Regarding Forward-Looking Statements
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects
- both business and financial. Although we believe that our plans, intentions and expectations reflected in or
suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these
plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions.
Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words
such as "believe," "expect," "anticipate," "should," "planned,"
"will," "may," "intend," "estimated," and "potential," among
others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in
this news release include market conditions and those set forth in reports or documents that we file from time to time with
the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or
a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
are the property of their respective owners.
Manuel Pi eiro Dagnery
and Investor Relations Contact